Ustekinumab (approximately 6 mg/kg)

DRUG3 trials

Sponsors

Janssen Research & Development, LLC, Sixth Affiliated Hospital, Sun Yat-sen University

Conditions

Crohn's Disease AggravatedCrohn's Disease in RemissionLupus Erythematosus, Systemic

Phase 3

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

TerminatedNCT03517722

Janssen Research & Development, LLCLupus Erythematosus, Systemic

Start: 2018-04-16End: 2020-11-05Updated: 2025-04-29

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

WithdrawnNCT04060888

Janssen Research & Development, LLCLupus Erythematosus, Systemic

Start: 2020-07-14End: 2026-03-31Updated: 2025-02-03

Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study

Not yet recruitingNCT07149467

Sixth Affiliated Hospital, Sun Yat-sen UniversityCrohn's Disease Aggravated, Crohn's Disease in Remission

Start: 2025-09-10End: 2027-12-31Target: 454Updated: 2025-09-02

Related Papers

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.

2022-10-1249 citations

03 Targeting interleukin 12/23

2019-09-01